comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers全面的血清分析发现上皮卵巢癌生物标记.pdfVIP

Comprehensive Serum Profiling for the Discovery of Epithelial Ovarian Cancer Biomarkers 1 1 1 2 2 Ping Yip , Tzong-Hao Chen , Partha Seshaiah , Laurie L. Stephen , Karri L. Michael-Ballard , James P. 2 1¤ 1 Mapes , Brian C. Mansfield , Greg P. Bertenshaw * 1 Correlogic Systems, Inc., Germantown, Maryland, United States of America, 2 Rules-Based Medicine, Inc., Austin, Texas, United States of America Abstract FDA-cleared ovarian cancer biomarkers are limited to CA-125 and HE4 for monitoring and recurrence and OVA1, a multivariate panel consisting of CA-125 and four additional biomarkers, for referring patients to a specialist. Due to relatively poor performance of these tests, more accurate and broadly applicable biomarkers are needed. We evaluated the dysregulation of 259 candidate cancer markers in serum samples from 499 patients. Sera were collected prospectively at 11 monitored sites under a single well-defined protocol. All stages of ovarian cancer and common benign gynecological conditions were represented. To ensure consistency and comparability of biomarker comparisons, all measurements were performed on a single platform, at a single site, using a panel of rigorously calibrated, qualified, high-throughput, multiplexed immunoassays and all analyses were conducted using the same software. Each marker was evaluated independently for its ability to differentiate ovarian cancer from benign conditions. A total of 175 markers were dysregulated in the cancer samples. HE4 (AUC = 0.933) and CA-125 (AUC = 0.907) were the most informative biomarkers, followed by IL-2 receptor a, a1-antitrypsin, C- reactive prote